CYBIN INC.
HELPDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Aug 12, 2026
7dMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
HELP Earnings Report
EPS Est: $-0.80 | FQ end 2026-06
CYB003 Phase 3 Est. Readout
Primary completion for CYB003 trial (NCT06564818) in Major Depressive Disorder
Auto-detected: positive
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How HELP's past catalysts played out
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in CYBIN INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in CYBIN INC.'s (HELP) pipeline across Phase 3, Phase 2. Its lead program is CYB003 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CYBIN INC.'s next FDA catalyst?→
CYBIN INC.'s (HELP) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HELP biotech catalysts?→
Add HELP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CYBIN INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.